Nicole Mairon

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

8h-index4.8kcitations22works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(14), Bone health and osteoporosis research(13), Multiple Sclerosis Research Studies(4), Bone Metabolism and Diseases(4), Peripheral Neuropathies and Disorders(3)

Publications22 total

WED 187 Infections in ocrelizumab recipients from phase III studies
Journal of Neurology Neurosurgery & Psychiatry·2018
PO128 Infusion-related reactions with ocrelizumab in rms and ppms
Journal of Neurology Neurosurgery & Psychiatry·2017
Infections et infections sévères chez les patients atteints de sclérose en plaques récurrente ou primaire progressive traités par ocrelizumab. Résultats des études OPERA I, OPERA II et ORATORIO
Revue Neurologique·2017
Réactions liées à la perfusion chez des patients atteints de de sclérose en plaques récurrente ou primaire progressive traités par ocrelizumab. Résultats des études OPERA I, OPERA II et ORATORIO
Revue Neurologique·2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
New England Journal of Medicine·2016· 1.9k citedOpen Access
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
New England Journal of Medicine·2016· 1.8k citedOpen Access
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
Osteoporosis International·2011· 162 cited
Safety and Tolerability of Bazedoxifene in Postmenopausal Women With Osteoporosis: Results of a 5-year, Randomized, Placebo-controlled Phase 3 Trial
Bone·2010· 13 citedOpen Access
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
PubMed·2008· 161 cited
Once-monthly dosing of oral ibandronate is highly efficacious: 2-year results from mobile
Open Repository and Bibliography (University of Liège)·2006
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
Annals of the Rheumatic Diseases·2005· 329 citedOpen Access
Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
Open Repository and Bibliography (University of Liège)·2005· 1 cited
Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study
Journal of Bone and Mineral Research·2005· 333 cited
Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study
Open Repository and Bibliography (University of Liège)·2005· 4 citedOpen Access
Once-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE
Open Repository and Bibliography (University of Liège)·2005Open Access
Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE
Open Repository and Bibliography (University of Liège)·2005Open Access
Monthly oral ibandronate is at least as effective as daily oral ibandronate: 1-year results from MOBILE
Open Repository and Bibliography (University of Liège)·2005
Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis : 1-year results from mobile
Open Repository and Bibliography (University of Liège)·2005
Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
Journal of Bone and Mineral Research·2005· 2 cited
Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.
Arthritis & Rheumatism·2005
page 1 of 2Next →

Frequent Co-authors

Claire Hughes(10), Jean‐Yves Reginster(9), Cyrus Cooper(7), B Bonvoisin(7), Dieter Felsenberg(6), Jerry S. Wolinsky(5), Ludwig Kappos(5), J. A. Stakkestad(5), Pierre D. Delmas(5), Stephen L. Hauser(4), Bernhard Hemmer(4), J. de Sèze(4), Amit Bar‐Or(3), Fred Lublin(3), Xavier Montalbán(3), Bernard Bonvoisin(3), Robert R. Recker(3), David L. Kendler(3), Maria Greenwald(3), Lorenc Rs(3)